Determining Best or Inferior Drug(s) Using an Adaptive Platform for Cryptogenic Sensory Polyneuropathy

Authors

  • Richard J. Barohn
  • Jeffery Allen University of Minnesota School of Medicine
  • David Avila Geisinger Medical Center
  • Alexandru Barboi Northshore University HealthSystem
  • Suur Biliciler McGovern Medical School
  • Charles Abrams The University of Chicago Medicine
  • Thomas Brannagan III Columbia University
  • Michael Cartwright Wake Forest School of Medicine
  • Nizar Chahin Oregon Health & Science University
  • Jasvinder Chawla Loyola University Medical Center
  • Miguel Chuquilin
  • Michael Collins Medical College of Wisconsin
  • Anahita Deboo Lewis Katz School of Medicine at Temple University
  • John England Louisiana State University
  • Joseph Americo Fernandes Nebraska Medicine
  • Miriam Friemer The Ohio State University Wexner Medical Center
  • Stefanie Geisler Washington University St. Louis
  • Steven Herskovitz Albert Einstein College of Medicine
  • Neil Holland University of Florida
  • Carlayne Jackson UT Health San Antonio
  • Vern Juel Duke Health
  • David Lacomis University of Pittsburgh
  • Maxwell Levy Tulane School of Medicine
  • Rabia Malik Rush University Medical Center
  • Daniela Menichella Northwestern Medicine
  • Sharon Nations UT Southwestern Medical Center
  • Amanda Peltier Vanderbilt University
  • Michael Pulley University of Florida Health
  • Kourosh Rezania The University of Chicago Medicine
  • Jessica Robinson-Papp Mount Sinai
  • Katherine Ruzhansky Medical University of South Carolina
  • Khema Sharma University of Miami Health
  • Amro Stino University of Michigan
  • Xiaowei Su Penn State Health
  • Andrea Swenson University of Iowa Hospitals
  • Pariwat Thaisetthawatkul University of Nebraska Medical Center
  • Sujata Thawani NYU Langone Health
  • Rebecca Traub University North Carolina School of Medicine

DOI:

https://doi.org/10.17161/rrnmf.v3i2.18133

Keywords:

letter

Downloads

Download data is not yet available.

Downloads

Published

2022-06-22

How to Cite

Barohn, R. J., Allen , J. ., Avila, D., Barboi, A., Biliciler , S., Abrams , C. ., Brannagan III, T. ., Cartwright , M. ., Chahin, N., Chawla, J., Chuquilin, M. ., Collins, M. ., Deboo, A. ., England, J. ., Fernandes, J. ., Friemer , M. ., Geisler, S. ., Herskovitz , S. ., Holland, N. ., Jackson, C., Juel , V. ., Lacomis, D., Levy, M., Malik , R. ., Menichella, D. ., Nations, S. ., Peltier, A. ., Pulley, M. ., Rezania, K. ., Robinson-Papp, J. ., Ruzhansky, K. ., Sharma, K. ., Stino, A. ., Su, X. ., Swenson , A. ., Thaisetthawatkul, P. ., Thawani, S. ., & Traub , R. . (2022). Determining Best or Inferior Drug(s) Using an Adaptive Platform for Cryptogenic Sensory Polyneuropathy. RRNMF Neuromuscular Journal, 3(2), 45–98. https://doi.org/10.17161/rrnmf.v3i2.18133

Issue

Section

Proposed Stuff (Funded or unfunded grant proposals)